{"id":3800,"date":"2021-05-14T16:30:00","date_gmt":"2021-05-14T20:30:00","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=3800"},"modified":"2022-06-23T11:27:14","modified_gmt":"2022-06-23T15:27:14","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"\r\n<p>Palo Alto, CA, May 14, 2021 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted 27 new employees restricted stock units for an aggregate of 70,949 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan).<\/p>\r\n\r\n\r\n\r\n<p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio<\/strong><br \/>BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the Company\u2019s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit <a href=\"http:\/\/bridgebio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>Media Contact:<\/strong><strong><br \/><\/strong>Grace Rauh<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I1UvdWFu9E6zR5LihmNuSOlR4mUuKLOnccRynXRmMp1y3Zivw6HhTYOvLSNDb6YoR8y8Yqn782EVcVlveWIAMJS7arKQrcvRnA2_ORt8eJU=\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Grace.rauh@bridgebiodev.wpengine.com<\/strong><\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Palo Alto, CA, May 14, 2021 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021, the compensation committee of BridgeBio\u2019s board of directors granted 27 new employees restricted stock units for an aggregate of 70,949 shares of the Company\u2019s common stock. All of [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-3800","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"external_link":"","presentation":"","meta_short_title":"BridgeBio Reports Inducement Grants","meta_description":"","meta_share_image":false,"people":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inducement Grants | 5\/14\/21 | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inducement Grants | 5\/14\/21 | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-14T20:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T15:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Cybele Gouverneur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cybele Gouverneur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/\",\"name\":\"Inducement Grants | 5\/14\/21 | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2021-05-14T20:30:00+00:00\",\"dateModified\":\"2022-06-23T15:27:14+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\"},\"description\":\"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\",\"name\":\"Cybele Gouverneur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"caption\":\"Cybele Gouverneur\"},\"url\":\"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inducement Grants | 5\/14\/21 | BridgeBio","description":"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/","og_locale":"en_US","og_type":"article","og_title":"Inducement Grants | 5\/14\/21 | BridgeBio","og_description":"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/","og_site_name":"BridgeBio","article_published_time":"2021-05-14T20:30:00+00:00","article_modified_time":"2022-06-23T15:27:14+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Cybele Gouverneur","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Cybele Gouverneur","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/","name":"Inducement Grants | 5\/14\/21 | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2021-05-14T20:30:00+00:00","dateModified":"2022-06-23T15:27:14+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7"},"description":"BridgeBio announced that on May 4, 2021, the compensation committee granted 27 new employees restricted stock units for an aggregate of 70,949 shares.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7","name":"Cybele Gouverneur","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","caption":"Cybele Gouverneur"},"url":"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/3800"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=3800"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/3800\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=3800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=3800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=3800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}